How to use this document
Copy the template below into your quality system. Replace every <<FILL: ...>> placeholder with your company, system, and process specifics, then route it through your own document control, review, and approval. The filled specimen shows one worked example; adapt the numbers and scope to your operation and verify each cited regulation or standard against the current source before you rely on it.
This is a generic, originally worded starting point. It contains no confidential, proprietary, or employer material, it is drafted with AI assistance and reviewed, it is not legal or compliance advice, and adopting it does not by itself create or prove compliance. See the Disclaimer and Terms.
This is a ready-to-use periodic Continued Process Verification (CPV) trend summary report. It is not the annual product review (APR) or product quality review (PQR); it is a shorter, more frequent document that sits between the individual chart and the APR, so a reviewer can read what every monitored parameter did this period in one place, and so the APR has a single, dated document to cite instead of someone’s recollection of what last quarter’s charts looked like. Replace every <<FILL: ...>> placeholder with your own specifics and route it through your normal document control and review. A filled specimen follows. Verify each cited reference against the current source before you rely on it.
1. Purpose
This report summarizes, for the stated period, what every parameter monitored under the CPV plan referenced above showed, what signals fired, what was investigated, and what remains open, in one document that stands between an individual chart review and the annual product review or product quality review. It does not replace either; it gives both a common, dated statement of CPV status to draw from, so a periodic conclusion and the later APR/PQR conclusion for the same period are never found disagreeing after the fact.
2. Scope
3. Responsibilities
4. Prerequisites
Do not compile this report until the following are confirmed true for the period covered.
5. Reporting period summary
6. Parameter-by-parameter trend summary
Add one row per monitored parameter. A reviewer conclusion of “no concerns” with nothing else stated, repeated unchanged period after period, does not meet this report’s bar; state what the chart actually showed, even when the answer is that nothing changed.
7. Open items carried from the prior period
State explicitly “none” if no items carried forward, rather than leaving the section blank.
8. New items this period
9. Program coverage check
10. Overall conclusion
State a specific conclusion for the period, naming any open signal explicitly rather than issuing a general statement of control. A conclusion of “state of control maintained” sitting next to an unresolved open item in section 7 is the exact pattern this report exists to prevent.
11. Handoff to the annual product review
12. References
FDA guidance, “Process Validation: General Principles and Practices” (January 2011), Stage 3.
21 CFR 211.180(e), Annual Product Review.
ICH Q10, Pharmaceutical Quality System.
Confirm the current version of each reference before issue.
13. Revision history
14. Approvals
Filled specimen
Extract for an example oligonucleotide drug substance program, third quarter of 2026. Company and numbers are illustrative.
The specimen shows what the report is built to do: it names the one open item specifically rather than issuing a blanket clean statement, and it hands that exact status forward to the APR author instead of leaving the APR to independently rediscover it from the raw chart.
Common inspection findings this report prevents
- A CPV program with charts updated every batch but no document anyone reads between APR cycles, so a trend sits unnoticed for most of a year.
- A periodic report’s reviewer conclusion copied forward unchanged from the prior period, discovered when a reviewer compares two consecutive reports side by side.
- An open signal visible in a quarterly report that the APR, written months later, never mentions, because the two documents were never reconciled.
- A parameter added to or dropped from the monitored set with no corresponding update to the traceability matrix or a stated reason here.
How to adapt this report
- Set your own reporting cadence in section 2; quarterly is common for a program with meaningful batch volume, but state the basis if a lower-volume program needs a longer interval.
- Build section 6 directly from the current traceability matrix so every parameter has a row; do not summarize only the parameters that happened to show something interesting this period.
- Treat section 7 as a running thread across reports, not a fresh list each time; a signal that closes should show its closure here, not simply disappear from the next report.
- Confirm section 10’s conclusion against section 7’s open items before approval, and confirm it again against the APR once that document is drafted.
